In the second quarter, Steigerwald Gordon & Koch Inc. grew its position in Zoetis Inc. by 2.9%, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor now owns 88,817 shares of Zoetis, making the stock its 17th largest holding. The value of Steigerwald Gordon & Koch Inc.’s holdings in Zoetis at the end of the quarter was $15.3 million.
Other hedge funds have also made changes to their positions in Zoetis. Evermay Wealth Management LLC increased its position by 439.3% in the first quarter, while Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position by 430.8% in the same quarter. Worth Asset Management LLC and Pacifica Partners Inc. also increased their positions in the first and second quarters, respectively. HHM Wealth Advisors LLC increased its position by 1,160% in the first quarter. Hedge funds and other institutional investors now own 89.47% of Zoetis’ stock.
Zoetis Inc., a company with a market capitalization of $81.33 billion, is involved in the discovery, development, manufacturing, and commercialization of animal health medicines, vaccines, and diagnostic products. It primarily commercializes its products for livestock, such as cattle, swine, poultry, fish, and sheep, as well as companion animals like dogs, cats, and horses.
Zoetis’ performance on the stock market has been impressive, with a 1-year low of $124.15 and a 1-year high of $194.99. The company reported a revenue of $2.18 billion for the second quarter, beating the consensus estimate of $2.16 billion. Zoetis had a return on equity of 52.02% and a net margin of 26.92%. Equities analysts are predicting that the company will post an EPS of 5.42 for the current year.
In insider activity, EVP Robert J. Polzer sold 1,179 shares of the company’s stock in a transaction dated August 9th. CEO Kristin C. Peck also sold 13,000 shares on August 22nd. In the last ninety days, insiders have sold a total of 25,930 shares, representing 0.12% of the company’s stock.
Various research firms have given Zoetis a “buy” rating. The stock presently has an average rating of “Buy” and an average price target of $222.44.
Source: MarketBeat and SEC filing.
Definitions:
– Form 13F filing: A disclosure document that certain institutional investors are required to file with the SEC, which contains information about the fund’s investment holdings.
– Hedge fund: An investment fund that pools capital from accredited individuals or institutional investors and invests in a variety of assets, with the goal of high returns.
– Market capitalization: The total value of a company’s outstanding shares of stock, calculated by multiplying the share price by the number of shares outstanding.
– P/E ratio: Price-to-earnings ratio, a valuation ratio of a company’s current share price compared to its per-share earnings.
– Beta: A measure of a stock’s volatility compared to the overall market.
– EPS: Earnings per share, calculated as a company’s net income divided by the number of outstanding shares of common stock.
– Return on equity: A measure of profitability that indicates how much profit a company generates with the money shareholders have invested.
– Net margin: The percentage of revenue that remains as profit after deducting all expenses.
– Simple moving average: A calculation that takes the average of a given number of closing prices over a specific period of time.
– Insider activity: Buying or selling of a company’s stock by individuals who have access to non-public information about the company.
– Price target: The projected future price level of a company’s stock, as determined by an investment analyst.
– Revenue: The total amount of money that a company receives from its normal business activities, usually from the sale of goods or services.
– SEC: Securities and Exchange Commission, a U.S. government agency responsible for regulating the securities industry and enforcing securities laws.